National Cancer Institute
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From National Cancer Institute
Through a grant from the National Cancer Institute (NCI), Charles River Analytics is building a platform to collect and analyze biometric sensor data and connected devices used by cancer patients across the US. The goal of the project is to support large-scale population health research and to improve cancer outcomes.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.
Merck's Prevymis should benefit from the failure of ASP0113 in a late-stage trial treating cytomegalovirus in certain kidney transplant patients.
- Academic and Research Institutions